Management of Opioid-Induced Myoclonus in a 75-Year-Old on Chronic Oxycodone
This patient is experiencing opioid-induced myoclonus (OIM), a recognized neurotoxic effect of chronic opioid therapy that requires immediate opioid dose reduction or rotation to a different opioid, not dose escalation.
Immediate Assessment
First, verify this is truly myoclonus and not undertreated pain. Key distinguishing features of OIM include:
- Involuntary, shock-like muscle jerks that are NOT relieved by increasing opioid doses
- Often generalized rather than localized
- May be periodic or associated with altered mental status
- Dose-related but unpredictable in onset 1, 2
Critical pitfall: Do NOT interpret muscle twitching as breakthrough pain requiring more opioids—this will worsen the neurotoxicity 2.
Evaluate Contributing Factors
Check for conditions that increase OIM risk:
- Renal function: Oxycodone and its metabolites accumulate with renal impairment 3, 1
- Hydration status: Dehydration concentrates neurotoxic metabolites 1
- Concomitant medications: Benzodiazepines, antipsychotics, neuroleptics, or antidepressants potentiate risk 4, 5
- High cumulative opioid dose: 30 mg oxycodone after years of use suggests tolerance and likely dose escalation 1
The FDA label specifically warns that elderly patients (≥65 years) have increased sensitivity to oxycodone and require careful dose titration 3.
Management Algorithm
Step 1: Reduce or Rotate the Opioid
Primary intervention: Either reduce the oxycodone dose by 25-50% OR rotate to a different opioid entirely 3, 1. Opioid rotation is often more effective because:
- Different opioids have distinct metabolite profiles
- Neurotoxic metabolite accumulation is drug-specific
- Patients may tolerate alternative opioids without myoclonus 1
Step 2: Add Symptomatic Treatment
While adjusting opioids, initiate clonazepam (or another benzodiazepine) to suppress myoclonus 2, 6. This allows pain control maintenance while managing the adverse effect.
Important caveat: The 2020 ACEP guidelines strongly recommend against co-prescribing opioids with benzodiazepines due to respiratory depression risk 7. However, this applies to routine outpatient prescribing for pain management, not acute management of opioid neurotoxicity in a monitored ED setting. Use benzodiazepines cautiously with close monitoring.
Alternative: Dantrolene may be used if benzodiazepines are contraindicated 1.
Step 3: Address Reversible Factors
- Correct dehydration with IV fluids
- Review and discontinue any dopamine antagonists (antipsychotics, antiemetics like metoclopramide) 4
- Optimize renal function if impaired
What NOT to Do
Do not increase the oxycodone dose—this is the most critical error. A case report describes escalation from 22 mg/h to 717 mg/h morphine over 7 days in response to presumed "breakthrough pain," with no improvement in muscle hyperactivity because it was actually opioid toxicity 2.
Do not discharge on the same opioid regimen without dose adjustment or rotation 1.
Disposition and Follow-Up
- Observe in ED until myoclonus improves after intervention
- If rotating opioids, start at 50% equianalgesic dose of the new opioid to account for incomplete cross-tolerance 3
- Arrange close outpatient follow-up (within 48-72 hours) to reassess pain control and myoclonus
- Consider referral to pain management or palliative care for chronic opioid optimization
Evidence Strength
The mechanism of OIM involves accumulation of neuroexcitatory opioid metabolites, particularly in renal impairment, with Level II evidence supporting this phenomenon 1, 6. Multiple case series demonstrate resolution with dose reduction or opioid rotation 1, 2, 4. The FDA label for oxycodone emphasizes increased sensitivity in elderly patients and the need for careful titration 3.